From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: DEMG

Search articles by EPIC code

Deltex Medical – “year end trading update”. Er, what about the debt?!

Medical technology group Deltex (DEMG) states that it “is pleased to provide a trading update following the close of the financial year ended 31 December 2022” and that development “good progress” and “work on securing a small number of substantial orders within its International division” is continuing. So what of this and a current approaching 4% higher share price response to 1.35p?

Deltex Medical – “pleased to announce” year end update. Er, what about the “increased cash requirements”?!

Deltex Medical Group (DEMG) states that it “is pleased to announce that its year-to-date revenues are ahead of the group's full year 2021 revenue figures. In addition, the group has a large advanced opportunity in the pipeline which if successful, could provide a further boost to revenue in the short term”. What of this and the rest of a “Year end update” with the shares currently more than 19% up at 0.925p?

Deltex Medical – I having previously questioned ‘how’s the balance sheet now?’, a discounted fundraising...

Deltex Medical (DEMG) has announced that “the board has concluded that it is now appropriate to raise a total of approximately £1.4 million… at a price of 1.25 pence per Deltex Medical ordinary share… (i) to launch, market and commercialise the next generation TrueVue monitor as well as a new non-invasive Doppler probe; (ii) to provide the financial resources required to support the substantial grant funding already won… and (iii) for the general working capital needs of the business”. Really?...


Deltex Medical – argues “a key opportunity”… but how’s the balance sheet now?

Haemodynamic monitoring technologies group Deltex Medical (DEMG) has made a “Pre-close statement”, noting that despite pandemic disruptions for the whole of the year this time, “revenues for the year ended 31 December 2021 were £2.3 million (2020: £2.4 million)” and belief that the backlog in elective surgery “represents a key opportunity for Deltex Medical as the group's TrueVue Doppler technology can be used to help minimise patient length of stay (and associated costs) following elective surgery and hence increase capacity for hospitals”. With also a ‘next generation’ TrueVue monitor due for release later this year, why a current share price fall to 1.25p?...

Page 1 of 2 (16 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments